Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 14/20 | 0.60 |
| ▸ | DRD1 | P21728 | 8/20 | 0.60 |
| ▸ | DRD2 | P14416 | 6/20 | 0.60 |
| ▸ | GRM5 | P41594 | 2/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31134854 | 0.95 | GRM5 (0.64) | DRD3DRD1DRD2GRM5DRD4 | |
| SCHEMBL5811132 | 0.95 | GRM5 (0.64) | DRD3DRD1DRD2GRM5DRD4 | |
| SCHEMBL5386472 | 0.85 | DRD3 (0.60) | DRD3DRD1DRD2DRD4 | |
| SCHEMBL1039709 | 0.85 | DRD3 (0.63) | DRD3DRD1DRD2DRD4 | |
| SCHEMBL18030756 | 0.84 | DRD2 (0.60) | DRD3DRD2 | |
| SCHEMBL29532002 | 0.84 | DRD2 (0.60) | DRD3DRD2 | |
| SCHEMBL1037156 | 0.84 | DRD3 (0.62) | DRD3DRD1DRD2DRD4 | |
| SCHEMBL18612248 | 0.83 | HTR7 (0.61) | DRD3DRD2 | |
| SCHEMBL30183548 | 0.83 | DRD3 (0.57) | DRD3DRD1DRD2DRD4 | |
| SCHEMBL13910341 | 0.83 | HTR7 (0.61) | DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116490201-A | Inhibitors of YAP/TAZ-TEAD tumor proteins, their synthesis and use | 布里奇恩生物科学公司 | 2023-07-25 | — | — | CN | disclosed |
| US-8501771-B2 | Aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-20090264403-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-10-22 | — | — | US | disclosed |
| US-20090082391-A1 | NOVEL AMINOALCOHOL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082391-A1 | NOVEL AMINOALCOHOL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, AHR, MCHR2 | DRD3 669/4885DRD1 542/4885DRD2 517/4885 |
| US-20090264403-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, MRGPRX1, MRGPRX4 | DRD3 1149/4885DRD1 1154/4885DRD2 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.